Caplin Point Lab

Why is Caplin Point Laboratories Ltd falling/rising?

As of 30-Jul, Caplin Point Laboratories Ltd's stock price is Rs 2,534.10, down 2.93%, with a notable decrease in investor participation. Despite strong long-term performance, recent trends indicate potential momentum shifts and concerns about valuation and growth prospects.

As of 30-Jul, Caplin Point Laboratories Ltd's stock price is falling, currently at Rs 2,534.10, reflecting a decrease of Rs 76.5 or 2.93%. This decline is evident in today's performance, where the stock underperformed its sector by 2.62% and reached an intraday low of Rs 2,515.7, marking a drop of 3.64%. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 23.18% compared to the 5-day average.<BR><BR>While the stock has shown strong performance over the long term, with a year-to-date increase of 37.63% and a 3-year return of 189.69%, the recent short-term trends indicate a struggle. The stock is currently trading below its 20-day moving average, despite being higher than the 5-day, 50-day, 100-day, and 200-day moving averages. This suggests a potential shift in momentum.<BR><BR>Moreover, the company's valuation appears expensive, with a Price to Book Value of 5.4, which is higher than its peers' average historical valuations. Although Caplin Point Laboratories has demonstrated high management efficiency and consistent positive results over the last 15 quarters, the operating profit growth rate of 18.73% over the last five years raises concerns about long-term growth prospects. These factors combined contribute to the current decline in the stock price.

Which are the latest news on Caplin Point Lab?

When is the next results date for Caplin Point Laboratories Ltd?

The next results date for Caplin Point Laboratories Ltd is 12 August 2026.

The next results date for Caplin Point Laboratories Ltd is scheduled for 12 August 2026.

Should I buy, sell or hold Caplin Point Laboratories Ltd?

How big is Caplin Point Lab?

As of 10th June, Caplin Point Laboratories Ltd has a market capitalization of 18,194.00 Cr, classifying it as a Small Cap company, with recent net sales of 2,187.19 Cr and a net profit of 641.24 Cr.

As of 10th June, Caplin Point Laboratories Ltd has a market capitalization of 18,194.00 Cr, which classifies it as a Small Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 2,187.19 Cr and a Net Profit of 641.24 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,850.49 Cr and Total Assets of 3,205.62 Cr.

Who are in the management team of Caplin Point Lab?

The management team of Caplin Point Lab includes C C Paarthipan (Chairman), D Sathyanarayanan, C K Gariyali, Deenadayalan Singaram, and R Nagendran (all Independent Directors), along with Sridhar Ganesan (Non-Independent Executive Director).

The management team of Caplin Point Lab includes the following members:<BR><BR>1. **C C Paarthipan** - Chairman & Non-Executive Director<BR>2. **D Sathyanarayanan** - Independent Non-Executive Director<BR>3. **C K Gariyali** - Independent Director<BR>4. **Deenadayalan Singaram** - Independent Non-Executive Director<BR>5. **R Nagendran** - Independent Non-Executive Director<BR>6. **Sridhar Ganesan** - Non-Independent Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Caplin Point Lab?

Caplin Point Lab's peers include Pfizer, OneSource Specialty, Granules India, ERIS Lifescience, Cohance Life, Natco Pharma, Jubilant Pharma, Alembic Pharma, and Concord Biotech. Notably, Granules India has the highest 1-year return at 45.79%, while Cohance Life has the lowest at -57.69%.

Peers: The peers of Caplin Point Lab are Pfizer, OneSource Speci., Granules India, ERIS Lifescience, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, and Concord Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Pfizer, Granules India, ERIS Lifescience, Natco Pharma, Alembic Pharma, and Concord Biotech, while Average management risk is found at Cohance Life and Jubilant Pharmo, and the rest have Good management risk. Growth is Excellent for OneSource Speci., while Below Average growth is seen at Pfizer, Granules India, ERIS Lifescience, Caplin Point Lab, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, and Concord Biotech. Excellent capital structure is noted for Pfizer, Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Alembic Pharma, and Concord Biotech, while Below Average capital structure is found at OneSource Speci., and the rest have Good capital structure.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 45.79%, while Cohance Life has the lowest at -57.69%. Caplin Point Lab's 1-year return of 10.69% is significantly higher than Cohance Life's. Additionally, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, and Concord Biotech all have negative six-month returns.

What does Caplin Point Lab do?

Caplin Point Laboratories Ltd is a small-cap pharmaceutical company that develops, produces, and markets generic and branded products. As of March 2026, it reported net sales of ₹600 Cr and a net profit of ₹170 Cr.

Overview:<BR>Caplin Point Laboratories Ltd is a fully integrated pharmaceutical company engaged in the production, development, and marketing of a wide range of generic formulations and branded products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>Caplin Point Laboratories Ltd was incorporated on April 16th, 1990. The company has maintained its status as a fully integrated pharma entity and reported its latest quarterly results for the period ending March 2026, showcasing significant sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 600 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 170 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 18,194 Cr (Small Cap) <BR><BR>Key Metrics:<BR>P/E: 27.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.31% <BR>Debt Equity: -0.28 <BR>Return on Equity: 17.88% <BR>Price to Book: 4.81 <BR><BR>Contact Details:<BR>Address: Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat Chennai Tamil Nadu : 600096 <BR>Tel: 91-44-24968000/71148000/28156653 <BR>Email: investor@caplinpoint.net/info@capli <BR>Website: http://www.caplinpoint.net

Are Caplin Point Laboratories Ltd latest results good or bad?

Caplin Point Laboratories Ltd's latest Q4 FY26 results are generally positive, with a net profit of ₹170.11 crores and revenue of ₹600.16 crores, both showing significant year-on-year growth. However, a decline in operating margin raises some concerns, and while the market reacted favorably, investors should be cautious about potential margin pressures.

Caplin Point Laboratories Ltd's latest results for Q4 FY26 can be considered good overall. The company reported a net profit of ₹170.11 crores, which is a 3.80% increase quarter-on-quarter and a significant 19.32% increase year-on-year. Revenue also showed strong growth, reaching ₹600.16 crores, up 10.57% from the previous quarter and 19.45% compared to the same quarter last year.<BR><BR>However, there are some concerns regarding the operating margin, which declined to 34.03% from 34.95% in the previous quarter, indicating some pressure on operational efficiency. Despite this, the overall financial performance reflects a positive trend, with record highs in revenue and profit levels.<BR><BR>The market reacted positively to these results, with the stock price jumping nearly 10% following the announcement. While the company has strong fundamentals, the valuation appears stretched, and investors should remain cautious about potential margin pressures moving forward. Overall, the results indicate a strong financial trajectory, but ongoing monitoring of margin dynamics will be important.

Is Caplin Point Lab technically bullish or bearish?

As of November 27, 2025, Caplin Point Lab's technical trend has shifted to bearish, driven by negative indicators such as a bearish MACD and moving averages, despite some bullish signals in the monthly OBV.

As of 27 November 2025, the technical trend for Caplin Point Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. The Dow Theory also indicates a mildly bearish trend on the weekly and monthly time frames. Despite some bullish signals in the monthly OBV, the overall technical picture remains negative.

How has been the historical performance of Caplin Point Lab?

Caplin Point Lab has shown consistent growth, with net sales increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25, alongside improvements in operating profit, profit before tax, and total assets. Overall, the company's financial performance indicates a strong upward trend across key metrics.

Answer:<BR>The historical performance of Caplin Point Lab shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Caplin Point Lab has demonstrated significant growth in net sales, increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. The company's operating profit (PBDIT) has similarly improved, reaching 743.36 Cr in Mar'25, up from 250.37 Cr in Mar'19. Profit before tax has followed suit, climbing from 226.88 Cr in Mar'19 to 676.79 Cr in Mar'25, while profit after tax increased from 176.56 Cr to 541.10 Cr over the same period. The company's total assets have expanded from 1,125.76 Cr in Mar'20 to 3,205.62 Cr in Mar'25, indicating robust asset growth. Shareholder's funds have also risen significantly, from 947.91 Cr in Mar'20 to 2,850.49 Cr in Mar'25. Cash flow from operating activities has improved, reaching 432.00 Cr in Mar'25, compared to 44.00 Cr in Mar'20, while net cash inflow turned positive at 60.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Caplin Point Lab's financial performance reflects a strong upward trend across various metrics, indicating a healthy and growing business.

Is Caplin Point Lab overvalued or undervalued?

As of June 8, 2023, Caplin Point Lab is considered very expensive and overvalued with a PE ratio of 29.63 and an EV to EBITDA of 23.18, especially when compared to peers like Cipla and Sun Pharma, and has recently declined by 4.29% while the Sensex increased by 1.43%.

As of 8 June 2023, the valuation grade for Caplin Point Lab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 29.63, an EV to EBITDA of 23.18, and a PEG ratio of 1.72, all suggesting a premium valuation compared to its earnings and growth potential.<BR><BR>In comparison with peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla presents a more attractive valuation with a PE of 22.99 and an EV to EBITDA of 15.93. The recent performance of Caplin Point Lab shows a 1-week decline of 4.29%, contrasting with a 1.43% increase in the Sensex, further reinforcing the notion of overvaluation in the current market environment.

Who are the top shareholders of the Caplin Point Lab?

The top shareholders of Caplin Point Lab include promoter P Vijayalakshmi with 24.71%, 17 mutual fund schemes holding 1.74%, 139 foreign institutional investors with 5.73%, and individual investors owning 15.11%. The highest public shareholder is Uti Small Cap Fund at 1.27%.

The top shareholders of Caplin Point Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is P Vijayalakshmi, who owns 24.71% of the company. Additionally, there are 17 mutual fund schemes that collectively hold 1.74%, and 139 foreign institutional investors (FIIs) with a combined holding of 5.73%. The highest public shareholder is Uti Small Cap Fund, which holds 1.27%. Individual investors also have a significant presence, holding 15.11% of the shares.

Has Caplin Point Lab declared dividend?

Yes, Caplin Point Laboratories Ltd has declared a 150% dividend, amounting to ₹3 per share, with an ex-date of May 30, 2025. The dividend yield is 0.26%, and the company has shown strong total returns over various periods.

Caplin Point Laboratories Ltd has declared a 150% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 3<BR>- Ex-date: May 30, 2025<BR><BR>Dividend Yield: 0.26%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.8%, the dividend return was 0.13%, resulting in a total return of -10.67%.<BR><BR>Over the past year, the price return was 60.93%, the dividend return was 0.38%, leading to a total return of 61.31%.<BR><BR>In the 2-year period, the price return was 170.89%, the dividend return was 1.29%, culminating in a total return of 172.18%.<BR><BR>For the 3-year period, the price return was 173.41%, with a dividend return of 2.11%, resulting in a total return of 175.52%.<BR><BR>In the last 4 years, the price return was 251.24%, the dividend return was 2.72%, giving a total return of 253.96%.<BR><BR>Finally, over the past 5 years, the price return was 540.68%, the dividend return was 5.90%, leading to a total return of 546.58%.<BR><BR>Overall, Caplin Point Laboratories Ltd has demonstrated significant total returns over various periods, with a notable dividend declaration, indicating a commitment to returning value to shareholders. The dividend yield, while modest, reflects a consistent approach to shareholder returns alongside strong price appreciation.